2020
DOI: 10.1177/1533033820962140
|View full text |Cite
|
Sign up to set email alerts
|

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer

Abstract: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) accounts for about 20% to 30% of all BC subtypes and is characterized by invasive disease and poor prognosis. With the emergence of anti-HER2 target drugs, HER2-positive BC patient outcomes have changed dramatically. However, treatment failure is mostly due to drug resistance and the special treatment needs of different subgroups. Small molecule tyrosine kinase inhibitors can inhibit multiple targets of the human epidermal growth facto… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 15 publications
(6 citation statements)
references
References 115 publications
0
6
0
Order By: Relevance
“…The HER2 family involves extracellular protein overexpression and intracellular point mutations, both of which can activate the downstream pathway. Primary resistance to the dual-targeted drugs, trastuzumab + pertuzumab, can be partially reversed by TKIs such as lapatinib, pyrotinib, and neratinib ( 20 ). TKIs inhibit multiple targets of the human epidermal growth factor receptor family intracellularly and also help regulate cell growth, differentiation, migration, and apoptosis.…”
Section: Discussion Of Therapeutic Strategies Of Anti-her2 Drugs Base...mentioning
confidence: 99%
“…The HER2 family involves extracellular protein overexpression and intracellular point mutations, both of which can activate the downstream pathway. Primary resistance to the dual-targeted drugs, trastuzumab + pertuzumab, can be partially reversed by TKIs such as lapatinib, pyrotinib, and neratinib ( 20 ). TKIs inhibit multiple targets of the human epidermal growth factor receptor family intracellularly and also help regulate cell growth, differentiation, migration, and apoptosis.…”
Section: Discussion Of Therapeutic Strategies Of Anti-her2 Drugs Base...mentioning
confidence: 99%
“…In this context, combination treatments based on the use of FAK inhibitors alongside chemotherapeutics, radiochemotherapeutics and immunotherapeutics would guarantee innovative options to halt the growth and metastatic spread of breast cancer. In this regard, new tyrosine kinase inhibitors (TKIs) have attracted attention in clinical settings for the synergistic repressive effects observed in combination with the endocrine therapies or monoclonal antibodies [229]. Moreover, immunotherapy combined with agents targeting VEGF, EGFR, PI3K, MEK, PARP and other chemotherapeutics has been shown to trigger clinical benefits in breast cancer patients [230,231].…”
Section: Discussionmentioning
confidence: 99%
“…The ErbB, HIF-1, JAK-STAT, MAPK, PI3K-Akt, and Ras pathways are the primary causes of resistance to chemo-and radio-therapeutics via upregulation of the proliferative, metastatic, migratory, invasive, cancerinitiating, and EMT capacities of HER2PBC cells and tumors; therapeutic suppression of these pathways can restore treatment sensitivity [62,64,[68][69][70][71][72][73][74]. The activity of these pathways may also be a potential indicator for the treatment response rate and survival outcomes of patients with HER2PBC [62,64,[68][69][70][71][72][73][74]. The p53 pathway is a key modulator of various stress responses and repair processes in cells [67].…”
Section: Dae-yeon Lee Et Almentioning
confidence: 99%